M.G. Schlieman

507 total citations
7 papers, 426 citations indexed

About

M.G. Schlieman is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, M.G. Schlieman has authored 7 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Oncology and 1 paper in Genetics. Recurrent topics in M.G. Schlieman's work include Peptidase Inhibition and Analysis (3 papers), Ubiquitin and proteasome pathways (3 papers) and Glycosylation and Glycoproteins Research (2 papers). M.G. Schlieman is often cited by papers focused on Peptidase Inhibition and Analysis (3 papers), Ubiquitin and proteasome pathways (3 papers) and Glycosylation and Glycoproteins Research (2 papers). M.G. Schlieman collaborates with scholars based in United States. M.G. Schlieman's co-authors include Richard J. Bold, Bridget N. Fahy, Rajendra Ramsamooj, Laurel Beckett, S. Virudachalam, Subbulakshmi Virudachalam, Melinda M. Mortenson, Joseph M. Galante, D. Gandara and Primo N. Lara and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Journal of Surgical Research.

In The Last Decade

M.G. Schlieman

7 papers receiving 418 citations

Peers

M.G. Schlieman

MB

ONCOL

CR

PFM

PRM

Marco Mazzoletti Italy

Thomas A. Lampkin United States

Eddie Reed United States

Elisa Brighenti Italy

Ramón González Manzano Spain

Samantha A. Streicher United States

Mark Cockerill United Kingdom

Harriet S. Walter United Kingdom

Z. Peter Wang China

Yoav Shetzer Israel

Marco Mazzoletti Italy

M.G. Schlieman

413 ×1.4

MB

182 ×0.8

ONCOL

97 ×1.1

CR

46 ×0.7

PFM

45 ×0.9

PRM

Citations per year, relative to M.G. Schlieman M.G. Schlieman (= 1×) peers Marco Mazzoletti

Countries citing papers authored by M.G. Schlieman

Since Specialization

Citations

This map shows the geographic impact of M.G. Schlieman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.G. Schlieman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.G. Schlieman more than expected).

Fields of papers citing papers by M.G. Schlieman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.G. Schlieman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.G. Schlieman. The network helps show where M.G. Schlieman may publish in the future.

Co-authorship network of co-authors of M.G. Schlieman

This figure shows the co-authorship network connecting the top 25 collaborators of M.G. Schlieman. A scholar is included among the top collaborators of M.G. Schlieman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.G. Schlieman. M.G. Schlieman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Schlieman, M.G., et al.. (2004). Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemotherapy and Pharmacology. 54(4). 343–53. 89 indexed citations

2.

Mortenson, Melinda M., M.G. Schlieman, S. Virudachalam, et al.. (2004). Effects of the 26S proteasome inhibitor, bortezomib, on BCL-2 in small cell lung cancer: Implications for SWOG-0327. Journal of Clinical Oncology. 22(14_suppl). 9560–9560. 2 indexed citations

3.

Galante, Joseph M., Melinda M. Mortenson, M.G. Schlieman, S. Virudachalam, & Richard J. Bold. (2004). Targeting NF-kB/BCL-2 pathway increases apoptotic susceptibility to chemotherapy in pancreatic cancer. Journal of Surgical Research. 121(2). 306–307. 11 indexed citations

4.

Mortenson, Melinda M., M.G. Schlieman, S. Virudachalam, et al.. (2004). Effects of the 26S proteasome inhibitor, bortezomib, on BCL-2 in small cell lung cancer: Implications for SWOG-0327. Journal of Clinical Oncology. 22(14_suppl). 9560–9560. 2 indexed citations

5.

Schlieman, M.G., Bridget N. Fahy, Rajendra Ramsamooj, Laurel Beckett, & Richard J. Bold. (2003). Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. British Journal of Cancer. 89(11). 2110–2115. 208 indexed citations

6.

Mortenson, Melinda M., et al.. (2003). Overexpression of BCL-2 results in activation of the AKT/NF-kB Cell survival pathway. Journal of Surgical Research. 114(2). 302–302. 14 indexed citations

7.

Fahy, Bridget N., M.G. Schlieman, S. Virudachalam, & Richard J. Bold. (2003). AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. British Journal of Cancer. 89(2). 391–397. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact